16th World ADC Europe 2026 focuses on maximizing the therapeutic index of antibody-drug conjugates (ADCs) and accelerating their development from concept to approved therapy.
We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.By clicking "Accept", you consent to our use of cookies. You can manage your preferences or learn more by clicking "Customize" or visiting our Cookies Policy page.